- Home
- GWH vs BLRX Comparison
GWH vs BLRX Comparison
Compare GWH & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- BLRX
- Stock Information
- Founded
- GWH 2011
- BLRX 2003
- Country
- GWH United States
- BLRX Israel
- Employees
- GWH N/A
- BLRX N/A
- Industry
- GWH Industrial Machinery/Components
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- GWH Miscellaneous
- BLRX Health Care
- Exchange
- GWH Nasdaq
- BLRX Nasdaq
- Market Cap
- GWH 17.1M
- BLRX 15.3M
- IPO Year
- GWH N/A
- BLRX 2011
- Fundamental
- Price
- GWH $1.20
- BLRX $4.45
- Analyst Decision
- GWH Hold
- BLRX Strong Buy
- Analyst Count
- GWH 5
- BLRX 2
- Target Price
- GWH $2.10
- BLRX $19.00
- AVG Volume (30 Days)
- GWH 2.2M
- BLRX 2.1M
- Earning Date
- GWH 08-13-2025
- BLRX 08-14-2025
- Dividend Yield
- GWH N/A
- BLRX N/A
- EPS Growth
- GWH N/A
- BLRX N/A
- EPS
- GWH N/A
- BLRX N/A
- Revenue
- GWH $4,155,999.00
- BLRX $22,340,000.00
- Revenue This Year
- GWH $179.38
- BLRX N/A
- Revenue Next Year
- GWH $175.77
- BLRX N/A
- P/E Ratio
- GWH N/A
- BLRX N/A
- Revenue Growth
- GWH N/A
- BLRX 91.68
- 52 Week Low
- GWH $0.76
- BLRX $2.30
- 52 Week High
- GWH $14.10
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- GWH 44.07
- BLRX 50.17
- Support Level
- GWH $0.95
- BLRX $3.79
- Resistance Level
- GWH $1.44
- BLRX $4.62
- Average True Range (ATR)
- GWH 0.12
- BLRX 0.56
- MACD
- GWH 0.05
- BLRX -0.13
- Stochastic Oscillator
- GWH 50.00
- BLRX 21.79
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.